13.02.2023 13:50:13
|
Ironwood Pharma: FDA Grants Priority Review To SNDA For LINZESS
(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD) announced the FDA has granted Priority Review to the supplemental New Drug Application for LINZESS for the treatment of children and adolescents ages 6-17 years-old with functional constipation. The FDA has assigned the application a PDUFA date of June 14th, 2023, four months earlier than the standard review cycle. The sNDA filing was based on the results of a large, multicenter, double-blind, Phase III study.
Tom McCourt, CEO of Ironwood Pharmaceuticals, said: "If approved, we look forward to a commercial launch mid-2023."
Shares of Ironwood Pharmaceuticals are up 4% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Ironwood Pharmaceuticals Inc (A)mehr Nachrichten
06.11.24 |
Ausblick: Ironwood Pharmaceuticals A vermeldet Zahlen zum jüngsten Quartal (finanzen.net) |
Analysen zu Ironwood Pharmaceuticals Inc (A)mehr Analysen
Aktien in diesem Artikel
Ironwood Pharmaceuticals Inc (A) | 1,91 | -0,52% |
|